News

A study from ACR Convergence details the underdiagnosis and undertreatment of osteoporosis in older men.

Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Lessons learned from antimalarial drug shortages during the COVID-19 pandemic: rheumatic disease patients in African and South-East Asia had difficulty obtaining antimalarials as compared to counterparts in the Americas and Europe. Shortages led to worse mental and physical health outcomes. Antimalarials did not protect patients from COVID-19.

Doctors increased their use of DEXA screening and initiate osteoporosis therapy more frequently after the implementation of an initiative to raise their awareness of the 2017 American College of Rheumatology (ACR) guidelines for the management of glucocorticoid-induced osteoporosis (GIOP), according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

The use of corticosteroid injections may not be associated with the progression of knee osteoarthritis to the point of total knee replacement any more than the use of hyaluronic acid, according to a presentation made today at the American College of Rheumatology annual meeting.

Black and Latinx COVID-19 patients in the United States who suffer from rheumatic conditions are more likely to require hospitalization and invasive ventilation than their White counterparts, a new study suggests.

Artificial intelligence (AI) detected axial spondyloarthritis (axSpA) in radiographic scans of sacroiliac joints as accurately as human experts, shows a new study.

Women whose autoimmune disorders cause interstitial lung disease may be able to get pregnant and give birth safely, researchers reported at the American College of Rheumatology annual meeting.

In a study that examined the long-term effectiveness of intravenous and subcutaneous abatacept (Orencia, Bristol-Myers Squibb) in patients with juvenile idiopathic arthritis (JIA), the treatment was safe and well-tolerated with no new safety risks identified, according to researchers reporting at the annual meeting of the American College of Rheumatology on Saturday.

In a study that examined the effects of guselkumab (Tremfya, Janssen) on fatigue in patients with psoriatic arthritis, the treatment reduced fatigue through one year, according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

An analysis of patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with an elevated C-reactive protein (CRP) and/or evidence of sacroiliitis on magnetic resonance imaging (MRI) found that secukinumab (Cosentyx, Novartis) use resulted in numerically higher treatment response rates than placebo.

In a study that explored the longitudinal racial disparities in rheumatoid arthritis treatment and emergency department use, black rheumatoid arthritis patients were found to be less likely to receive biologics and instead, be given a prescription for glucocorticoids, say researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

Results from a trial in England suggest fall prevention programs and interventions may not be reducing fall rates and fractures in older patients, but do point to other benefits from an exercise program.

A new study contributes to the growing discussion around rheumatic disease treatment disparities.

Beta blockers may slow the rate of bone loss that occurs as people age, a study published in JBMR Plus suggests.

Use of either oral or inhaled corticosteroids to manage asthma can increase the risk of osteoporosis and fragility fractures, suggest the findings of a large study published in Thorax.

Depression may be linked to an increased risk of rheumatoid arthritis, particularly patients taking antidepressants, shows a new study.

Weight fluctuation in rheumatoid arthritis patients appears to be associated with higher cardiovascular risk in patients with rheumatoid arthritis, especially if they are not overweight, shows a new study.

Just 2% of observed older men to experience an indicative fracture received a diagnosis and treatment for osteoporosis over a four-year period.

An analysis of data from more than 65k patients suggests low-dose CT scans could provide an opportunity to screen for osteoporosis in older patients.

New survey findings show the antimalarial drug's promotion for potential SARS-CoV-2 benefit early into the pandemic led to needing patients losing access.

Data suggest patients administered tofacitinib for their arthritis do not face worsened risk, severity of flu infection.

The first 3 months of the pandemic were marked by a significant rate of patients changing or discontinuing medication without clinician guidance.

New data show patients with arthritis and psoriasis are far more likely to quarantine and isolate than similar patients, differentiating by treatment type.

New data from ACR 2020 assure concerns that patients with arthritis who test positive for COVID-19 may be at worse risk of ICU admission or even death.

Risk of herpes zoster and creatine phosphokinase increased with use of upadacitinib.

Anti-inflammatory and immunosuppressive agents are the two primary classes of drugs used to treat lupus nephritis. Now, a new study shows that the addition of the monoclonal antibody belimumab to standard therapy may make a meaningful difference in this hard-to-treat patient population.

Although mortality rates for kidney transplant recipients with COVID-19 are known to be high, end stage kidney disease patients with COVID-19 appear to have a higher risk of mortality than patients with new kidneys.

A possible new treatment for advanced lupus nephritis passes a phase two trial, according to a study presented at Kidney Week, the annual meeting of the American Society for Nephrology. The treatment, a CD20 antagonist called obinutuzumab, led to improvements in 41 percent of patients with lupus nephritis—a condition that affects one in 60 people with systemic lupus.